recombinant)
Sponsors
Centre hospitalier universitaire de Liege, Gentofte Hospital, Pfizer Inc., Region Skane, Centre Hospitalier Annecy Genevois, Fondazione Penta Ets
Conditions
BronchiolitisInflammatory rheumatic diseaseRSV-infectionRespiratory Syncytial Virus (RSV)Respiratory syncytial virus infectionRespiratory tract infectionallogeneic - Hematopoietic Stem Cell Transplantationallogeneic haematopoietic stem cell transplant recipient
Phase 2
A Phase II randomized trial of RSV vaccination in allogeneic hematopoietic stem cell transplant recipients (RSV-Allo study)
RecruitingCTIS2024-513290-53-00
Start: 2024-11-07Target: 204Updated: 2025-05-05
Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial
RSVaxID
Not yet recruitingCTIS2025-524374-42-00
Target: 400Updated: 2026-07-06
Phase 3
Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)
Not yet recruitingCTIS2025-521755-23-00
Target: 2000Updated: 2025-10-21
Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial
Not yet recruitingCTIS2025-522194-11-00
Target: 400Updated: 2025-11-04
Phase 4
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above (DAN-RSV)
RecruitingCTIS2024-516600-42-00
Start: 2024-11-18Target: 890000Updated: 2025-11-03
Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.
Not yet recruitingCTIS2024-518191-31-00
Target: 180Updated: 2025-07-09